Overview


According to FutureWise analysis the market for malabsorption syndromes is expected to register a CAGR of 6.22% from 2023-2031.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Malabsorption Syndromes Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Malabsorption Syndromes Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AbbVie Inc.
  • ImmunogenX, LLC
  • AstraZeneca
  • ImmusanT, Inc.
  • Ritter Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Johnson and Johnson Services, Inc..
  • Biogen
  • MerckCo., Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Immunomedics, Inc.
  • Innovate Biopharmaceuticals
  • Kedrion Biopharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Celgene Corporation
  • Biotest Pharmaceuticals Corporation
  • BioLineRx Ltd
  • Bayer AG
  • Anthera Pharmaceuticals, Inc.
  • Amgen Inc.
  • Adma Biologics Inc.
  • ImmusanT, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Causative Diseases

  • Whipple’s Disease
  • Short Bowel Syndrome
  • Intestinal Disorders
  • Others

By Treatment Type

  • Nutritional Supplements
  • Gluten-Free Diet
  • Protease and Lipase Supplements
  • Others

By Diagnosis Type

  • Hematologic Tests
  • Imaging Studies
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Malabsorption Syndromes Market By Causative Diseases, By Treatment Type, By Diagnosis Type, By Route of Administration, By Distribution Channel, By End-Users and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Malabsorption Syndromes Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Malabsorption Syndromes Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Malabsorption Syndromes Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Malabsorption Syndromes Market, By Causative Diseases Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Whipple’s Disease
        2. Short Bowel Syndrome
        3. Intestinal Disorders
        4. Others

  • 8.   Malabsorption Syndromes Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Nutritional Supplements
        2. Gluten-Free Diet
        3. Protease and Lipase Supplements
        4. Others

  • 9.   Malabsorption Syndromes Market, By Diagnosis Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hematologic Tests
        2. Imaging Studies
        3. Others

  • 10.   Malabsorption Syndromes Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injectable

  • 11.   Malabsorption Syndromes Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 12.   Malabsorption Syndromes Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others

  • 13.   North America Malabsorption Syndromes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Malabsorption Syndromes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Malabsorption Syndromes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Malabsorption Syndromes Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •       1. AbbVie Inc.
               1.1. Company Overview
               1.2. Product Portfolio
               1.3. SWOT Analysis
               1.4. Financial Overview
               1.5. Strategic Overview
              2. ImmunogenX, LLC
                 2.1. Company Overview
                 2.2. Product Portfolio
                 2.3. SWOT Analysis
                 2.4. Financial Overview
                 2.5. Strategic Overview
             3. AstraZeneca
                 3.1. Company Overview
                 3.2. Product Portfolio
                 3.3. SWOT Analysis
                 3.4. Financial Overview
                 3.5. Strategic Overview
             4. ImmusanT, Inc.
                 4.1. Company Overview
                 4.2. Product Portfolio
                 4.3. SWOT Analysis
                 4.4. Financial Overview
                 4.5. Strategic Overview
             5. Ritter Pharmaceuticals
                 5.1. Company Overview
                 5.2. Product Portfolio
                 5.3. SWOT Analysis
                 5.4. Financial Overview
                 5.5. Strategic Overview
             6. F. Hoffmann-La Roche Ltd
                 6.1. Company Overview
                 6.2. Product Portfolio
                 6.3. SWOT Analysis
                 6.4. Financial Overview
                 6.5. Strategic Overview      
             7. Pfizer Inc.
                  7.1. Company Overview
                  7.2. Product Portfolio
                  7.3. SWOT Analysis
                  7.4. Financial Overview
                  7.5. Strategic Overview
             8. Johnson & Johnson Services, Inc.
                  8.1. Company Overview
                  8.2. Product Portfolio
                  8.3. SWOT Analysis
                  8.4. Financial Overview
                  8.5. Strategic Overview
             9. Biogen
                  9.1. Company Overview
                  9.2. Product Portfolio
                  9.3. SWOT Analysis
                  9.4. Financial Overview
                  9.5. Strategic Overview
             10. Merck & Co., Inc.
                   10.1. Company Overview
                   10.2. Product Portfolio
                   10.3. SWOT Analysis
                   10.4. Financial Overview
                   10.5. Strategic Overview
             11. Novartis AG
                   11.1. Company Overview
                   11.2. Product Portfolio
                   11.3. SWOT Analysis
                   11.4. Financial Overview
                   11.5. Strategic Overview      
             12. Bristol-Myers Squibb Company
                   12.1. Company Overview
                   12.2. Product Portfolio
                   12.3. SWOT Analysis
                   12.4. Financial Overview
                   12.5. Strategic Overview
             13. Immunomedics, Inc.
                   13.1. Company Overview
                   13.2. Product Portfolio
                   13.3. SWOT Analysis
                   13.4. Financial Overview
                   13.5. Strategic Overview
             14. Innovate Biopharmaceuticals
                   14.1. Company Overview
                   14.2. Product Portfolio
                   14.3. SWOT Analysis
                   14.4. Financial Overview
                   14.5. Strategic Overview
             15. Kedrion Biopharma Inc.
                   15.1. Company Overview
                   15.2. Product Portfolio
                   15.3. SWOT Analysis
                   15.4. Financial Overview
                   15.5. Strategic Overview
             16. Takeda Pharmaceutical Company Limited
                   16.1. Company Overview
                   16.2. Product Portfolio
                   16.3. SWOT Analysis
                   16.4. Financial Overview
                   16.5. Strategic Overview
             17. Celgene Corporation
                   17.1. Company Overview
                   17.2. Product Portfolio
                   17.3. SWOT Analysis
                   17.4. Financial Overview
                   17.5. Strategic Overview
             18. Biotest Pharmaceuticals Corporation
                   18.1. Company Overview
                   18.2. Product Portfolio
                   18.3. SWOT Analysis
                   18.4. Financial Overview
                   18.5. Strategic Overview
             19. BioLineRx Ltd
                   19.1. Company Overview
                   19.2. Product Portfolio
                   19.3. SWOT Analysis
                   19.4. Financial Overview
                   19.5. Strategic Overview
             20. Bayer AG
                   20.1. Company Overview
                   20.2. Product Portfolio
                   20.3. SWOT Analysis
                   20.4. Financial Overview
                   20.5. Strategic Overview
             21. Anthera Pharmaceuticals, Inc.
                   21.1. Company Overview
                   21.2. Product Portfolio
                   21.3. SWOT Analysis
                   21.4. Financial Overview
                   21.5. Strategic Overview
             22. Amgen Inc.
                   22.1. Company Overview
                   22.2. Product Portfolio
                   22.3. SWOT Analysis
                   22.4. Financial Overview
                   22.5. Strategic Overview
             23. Adma Biologics Inc.
                   23.1. Company Overview
                   23.2. Product Portfolio
                   23.3. SWOT Analysis
                   23.4. Financial Overview
                   23.5. Strategic Overview
             24. ImmusanT, Inc.
                   24.1. Company Overview
                   24.2. Product Portfolio
                   24.3. SWOT Analysis
                   24.4. Financial Overview
                   24.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients